Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,026,612 papers from all fields of science
Search
Sign In
Create Free Account
fowlpox-NY-ESO-1 vaccine
Known as:
rF-NY-ESO-1
A cancer vaccine consisting of a recombinant fowlpox virus vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
NY‐ESO‐1 specific antibody and cellular responses in melanoma patients primed with NY‐ESO‐1 protein in ISCOMATRIX and boosted with recombinant NY‐ESO‐1 fowlpox virus
Ji-Li Chen
,
Amina Dawoodji
,
+15 authors
V. Cerundolo
International Journal of Cancer
2015
Corpus ID: 44759680
Vaccination strategies based on repeated injections of NY‐ESO‐1 protein formulated in ISCOMATRIX particles (NY‐ESO‐1 ISCOMATRIX…
Expand
2013
2013
NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.
L. von Boehmer
,
Muriel Mattle
,
+10 authors
M. van den Broek
Cancer Immunity
2013
Corpus ID: 11302508
During cancer progression, malignant cells may evade immunosurveillance. However, evidence for immunological escape in humans is…
Expand
Highly Cited
2012
Highly Cited
2012
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
K. Odunsi
,
J. Matsuzaki
,
+14 authors
E. Jäger
Proceedings of the National Academy of Sciences
2012
Corpus ID: 1654504
Recombinant poxviruses (vaccinia and fowlpox) expressing tumor-associated antigens are currently being evaluated in clinical…
Expand
2004
2004
LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers
A. Bender
,
J. Karbach
,
+7 authors
E. Jäger
Cancer Cell International
2004
Corpus ID: 26623802
Study design Eligible patients (pts) for the first part of the study were HLA-A2+ with advanced NY-ESO-1/LAGE+ tumors assessed by…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE